EXXUA is the first new chemical entity (NCE) utilizing this single mechanism approved for the treatment of major depressive disorder. EXXUA’s approved labeling does not list sexual dysfunction as an adverse reaction. HOUSTON, Sept. 28, 2023 /PRNewswire/ — Fabre-Kramer Pharmaceuticals Inc….